BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 9736988)

  • 21. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum concentrations of transforming growth factor-beta 1 in patients with benign and malignant prostatic diseases.
    Wolff JM; Fandel TH; Borchers H; Jakse G
    Anticancer Res; 1999; 19(4A):2657-9. PubMed ID: 10470214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
    Noguchi M; Noda S
    J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Can the tumor stage of prostate carcinoma be determined with the aid of prostate-specific antigen?].
    Semjonow A; Hertle L
    Urologe A; 1995 Jul; 34(4):290-6. PubMed ID: 7545843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The value of prostate-specific antigen in therapy follow-up of prostatic carcinoma].
    Wirth MP; Pilarsky C
    Urologe A; 1995 Jul; 34(4):297-302. PubMed ID: 7545844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Osteoblastic flare assessed by serum alkaline phosphatase activity is an index of short duration of response in prostate cancer patients with bone metastases submitted to systemic therapy.Gruppo Onco Urologico Piemontese (G.O.U.P).
    Berruti A; Cerutti S; Fasolis G; Sperone P; Tarabuzzi R; Bertetto O; Pagani G; Zolfanelli R; Pallotti S; Bumma C; Fontana D; Rosseti SR; Dogliotti L; Angeli A
    Anticancer Res; 1997; 17(6D):4697-702. PubMed ID: 9494591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Usefulness of alpha1-antichymotrypsin-PSA complex for predicting bone metastases of prostate cancer.
    Kikuchi E; Nakashima J; Ishibashi M; Ohigashi T; Oya M; Nakagawa K; Miyajima A; Murai M
    Urology; 2006 Aug; 68(2):371-5. PubMed ID: 16904455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer?
    Tarle M; Kraljić I
    Anticancer Res; 1997; 17(3A):1531-4. PubMed ID: 9179191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer.
    Nakashima J; Sumitomo M; Miyajima A; Jitsukawa S; Saito S; Tachibana M; Murai M
    J Urol; 1997 May; 157(5):1736-9. PubMed ID: 9112516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The current role of prostatic acid phosphatase and prostate-specific antigen in the management of prostate cancer.
    Shetty SD; Cerny JC
    Henry Ford Hosp Med J; 1992; 40(1-2):93-8. PubMed ID: 1385363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum levels of prostate-specific antigen and vitamin D in peritoneal dialysis patients.
    Passadakis P; Ersoy F; Tam P; Memmos D; Siamopoulos K; Ozener C; Akçiçek F; Camsari T; Ates K; Ataman R; Vlachojannis J; Dombros N; Utas C; Akpolat T; Bozfakioglu S; Wu GG; Karayaylali I; Arinsoy T; Stathakis C; Yavuz M; Tsakiris D; Dimitriades A; Yilmaz ME; Gültekin M; Karayalçin B; Challa A; Polat N; Oreopoulos DG
    Adv Perit Dial; 2004; 20():203-8. PubMed ID: 15384827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metastatic prostate cancer in an asymptomatic patient with an initial prostate-specific antigen (PSA) serum concentration of 21,380 ng/ml.
    Persec Z; Persec J; Sović T; Romic Z; Bosnar Herak M; Hrgovic Z
    Onkologie; 2010; 33(3):110-2. PubMed ID: 20215802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic factors in metastatic prostate cancer.
    Yigitbasi O; Ozturk U; Goktug HN; Gucuk A; Bakirtas H
    Urol Oncol; 2011; 29(2):162-5. PubMed ID: 19450995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and imaging correlations of bone turnover markers in prostate cancer patients with bone only metastases.
    Zafeirakis AG; Papatheodorou GA; Limouris GS
    Nucl Med Commun; 2010 Mar; 31(3):249-53. PubMed ID: 20038858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Correlation of procollagen (I) with prostate specific antigen and bone scan for the diagnosis of bone metastases in patients with prostate carcinoma].
    Zissimopoulos A; Stellos C; Petrakis G; Baziotis N
    Hell J Nucl Med; 2004; 7(3):162-7. PubMed ID: 15841291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
    Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
    Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients.
    Lorente JA; Valenzuela H; Morote J; Gelabert A
    Eur J Nucl Med; 1999 Jun; 26(6):625-32. PubMed ID: 10369948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
    Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB
    Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
    Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
    Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.